Starling Oncology (STLNW) Intangibles (2020 - 2026)

Starling Oncology (STLNW) has reported Intangibles for 7 consecutive years, with $9.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Intangibles fell 23.01% year-over-year to $9.6 million; the trailing twelve-month figure through Jun 2026 stood at $9.6 million (down 23.01% YoY), and the FY2025 full-year result was $11.0 million, down 25.62% from the prior year.
• Intangibles retreated to $9.6 million in Q2 2026 per STLNW's latest filing, from $10.3 million in the prior quarter.
• Across five years, Intangibles topped out at $19.4 million in Q2 2022 and bottomed at $9.6 million in Q2 2026.
• Historically, Intangibles has averaged $15.5 million across 5 years, with a median of $16.7 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Intangibles decreased 0.2% in 2023, then decreased 26.62% in 2026.
• Over 5 years, Intangibles stood at $18.0 million in 2022, then fell by 0.3% to $17.9 million in 2023, then fell by 17.28% to $14.8 million in 2024, then fell by 25.62% to $11.0 million in 2025, then retreated by 12.98% to $9.6 million in 2026.
• According to Business Quant data, Intangibles over the past three periods registered $9.6 million, $10.3 million, and $11.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.